Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest gene delivery Stories

2013-04-03 16:24:48

TransIT®-BrCa Transfection Reagent for Breast Cancer Cell Research from Mirus Bio MADISON, Wis., April 3, 2013 /PRNewswire/ -- Mirus Bio has expanded its transfection expertise with the development of the TransIT-BrCa Transfection Reagent a high performance, low toxicity, DNA transfection reagent specifically formulated for breast cancer cell types. This new reagent offers users: Superior DNA Delivery--Achieve high expression levels in breast cancer cell types including: MCF-7,...

2013-02-05 12:27:35

NEW YORK, Feb. 5, 2013 /PRNewswire-USNewswire/ -- For over a century, each year has been marked by extraordinary progress in both medicine and biotechnology. Just one hundred years ago, Nicholay Anichkov made the earliest link between cholesterol and atherosclerosis, and Ernest Rutherford and Niels Bohr presented their models--physical and quantum--of the atom. 2013 will not only keep up pace, but will mark an extraordinary period of growth and development in the field of nanodermatology. The...

2013-01-22 08:30:59

AMSTERDAM, January 22, 2013 /PRNewswire/ -- uniQure B.V., the leader in the field of human gene therapy, today announced the appointment of Philip Astley-Sparke, former President and CEO of BioVex, as President US to provide strategic leadership and help build uniQure's clinical, regulatory, and commercial infrastructure in the US. Since May 2012, Philip is a venture partner at Forbion Capital Partners, uniQure's largest investor. As a venture partner he works with...

2013-01-20 23:02:04

[130 Slides Report]Global Transfection Technologies Market (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) (2012 — 2017) (PRWEB) January 20, 2013 The report "Global Transfection Technologies Market - (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA...

2012-12-14 04:23:32

DALLAS, December 14, 2012 /PRNewswire/ -- The report "Global Transfection Technologies Market [http://www.marketsandmarkets.com/Market-Reports/transfection-technologies-market-895.html ] - (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) And Types (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) (2012 - 2017) " defines and segments the global Transfection market with analysis of forecasting of the global revenue...

2012-12-06 04:23:38

AMSTERDAM, The Netherlands, December 6, 2012 /PRNewswire/ -- uniQure B.V., a leader in the field of human gene therapy, today announced the appointment of Hans Christian Rohde as Chief Commercial Officer. Mr. Rohde joins uniQure from Basilea Pharmaceutica (SIX: BSLN) where from 2007 he was Chief Commercial Officer and member of the company's executive management committee with responsibility for global commercial operations, marketing, supply chain, medical affairs,...

2012-12-05 04:21:49

AMSTERDAM, The Netherlands, December 5, 2012 /PRNewswire/ -- uniQure B.V., a leader in the field of human gene therapy, today announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. (ASX: BLT) giving uniQure access to Benitec's proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington's disease. In return, uniQure granted Benitec non-exclusive access to the Company's AAV5 delivery technology for the development of a ddRNAi therapy for...

2012-12-03 16:23:40

CAMBRIDGE, Mass., Dec. 3, 2012 /PRNewswire/ --Scientists find that games and graphics help break down complex topics like plasmid cloning. (Photo: http://photos.prnewswire.com/prnh/20121203/PH22695 ) Plasmid Land is a simplistic game created to explain the importance of plasmid cloning in science. It shows that using a plasmid repository can save an incredible amount of time in biological research. Additionally, it shows the steps of molecular cloning including gene extraction and...

European Union Approves New Gene Therapy Drug
2012-11-02 13:12:54

Lee Rannals for redOrbit.com — Your Universe Online A drug that has the ability to correct errors in a genetic code has been approved for the first time ever in Europe. The European Commission has given Glybera authorization to sell the drug next summer for treating an ultra rare genetic disease. The small Dutch biotech company's drug will cost around $1.6 million per patient, a new record price for medicine. The drug is a gene therapy for a rare disease that leaves people...

2012-11-02 03:20:30

AMSTERDAM, The Netherlands, November 2, 2012 /PRNewswire/ -- - Glybera [http://www.uniqure.com/uploads/Glybera 2pp Factsheet_lr.pdf ] becomes the first gene therapy approved by regulatory authorities in the Western world - First medication approved for patients with rare metabolic disorder Lipoprotein Lipase Deficiency - Commercial roll-out to begin second half of2013 - Validates uniQure's unique AAV-based gene...